Table 5.
Difference in mean scores on secondary outcomes between PTA and TAU groups at 16 weeks (intention-to-treat population)
| n, mean (SD) | GLM analysis | |||
|---|---|---|---|---|
| Variable | PTA | TAU | Difference and 95%CI | p-value |
| QoL (PDQQoL-39) | 68,155.47 (28.16) | 89,150.75 (25.62) | −0.22 (−3.95,3.52) | 0.9102 |
| Patient-Centred Questionnaire for Parkinson’s Disease (PCQ-PD) | 68,2.03 (0.48) | 89,1.85 (0.54) | 0.15 (0.03,0.27) | 0.0110 |
| Non-Motor Symptoms Questionnaire (NMSQuest) | 68,9.82 (5.68) | 89,10.66 (4.89) | −0.82 (−1.75,0.10) | 0.0822 |
| Hospital Anxiety Rating Scale (HADSa) | 68,6.03 (4.15) | 89,6.31 (4.21) | 0.30 (−0.42,1.01) | 0.4136 |
| Hospital Depression Rating Scale (HADSd) | 68,5.26 (3.73) | 89,5.53 (3.90) | 0.03 (−0.63,0.70) | 0.9195 |
| Beliefs about Medication Questionnaire (BMQ) | 68,51.84 (8.85) | 89,52.19 (7.97) | −0.42 (−2.16,1.32) | 0.6355 |
GLM generalised linear model, PTA Parkinson’s tracker app, TAU treatment as usual